Advertisement
Screener

INCYTE CORPORATION (INCY) Overview

INCYTE CORPORATION (INCY) Overview

  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 1.47; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 2.11; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 2.04; Beat / miss (m).
  • 1 Jan 2025: Period ending 31 Mar 2025; Estimate (m); Actual 0.80; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$85.79$94.13$103.28$113.32$124.34$136.432025-11-062026-11-06$48.62$59.76$73.46$90.30$110.99$136.432021-11-082026-11-06$48.62$61.72$78.35$99.47$126.27$160.292016-11-072026-11-06$1.95$4.71$11.37$27.46$66.35$160.292006-11-062026-11-06$1.63$4.09$10.23$25.60$64.06$160.291993-11-042026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$119.69
Previous close
$123.20
Change
-$3.51
Change (%)
-2.85%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

INCY
+24.72%
S&P 500
(m)

1 year

INCY
+46.85%
S&P 500
(m)

3 years

INCY
+113.24%
S&P 500
(m)

5 years

INCY
+79.39%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

31 Mar 2026 ○ Estimate (m) ● Actual 1.47

0.460.921.381.832.2930 Sept 2024: estimate (m); actual 0.5430 Sept 2024(m)31 Mar 2025: estimate (m); actual 0.8031 Mar 2025(m)30 Jun 2025: estimate (m); actual 2.0430 Jun 2025(m)30 Sept 2025: estimate (m); actual 2.1130 Sept 2025(m)31 Mar 2026: estimate (m); actual 1.4731 Mar 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202631 Mar 2026(m)1.47(m)(m)
1 Jul 202530 Sept 2025(m)2.11(m)(m)
1 Apr 202530 Jun 2025(m)2.04(m)(m)
1 Jan 202531 Mar 2025(m)0.80(m)(m)
1 Jul 202430 Sept 2024(m)0.54(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 6.41

0.071.703.334.966.5931 Dec 2021: estimate (m); actual 4.2731 Dec 2021(m)31 Dec 2022: estimate (m); actual 1.5231 Dec 2022(m)31 Dec 2023: estimate (m); actual 2.6531 Dec 2023(m)31 Dec 2024: estimate (m); actual 0.1531 Dec 2024(m)31 Dec 2025: estimate (m); actual 6.4131 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)6.41(m)(m)
1 Jan 202431 Dec 2024(m)0.15(m)(m)
1 Jan 202331 Dec 2023(m)2.65(m)(m)
1 Jan 202231 Dec 2022(m)1.52(m)(m)
1 Jan 202131 Dec 2021(m)4.27(m)(m)

Revenue vs. Earnings

USD

31 Mar 2026 ■ Revenue 1.27B ■ Earnings 0.30B — Profit margin 23.83%

-0.18B18.9%0.44B24.0%1.06B29.2%1.69B34.3%30 Jun 2025: revenue 1.22B; earnings 0.40B; profit margin 33.32%30 Jun 202530 Sept 2025: revenue 1.37B; earnings 0.42B; profit margin 31.05%30 Sept 202531 Dec 2025: revenue 1.51B*; earnings 0.30B*; profit margin 19.86%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 1.27B; earnings 0.30B; profit margin 23.83%31 Mar 2026

31 Dec 2025 ■ Revenue 5.14B ■ Earnings 1.29B — Profit margin 25.03%

-0.62B-0.2%1.51B8.5%3.63B17.3%5.76B26.0%31 Dec 2022: revenue 3.39B; earnings 0.34B; profit margin 10.04%31 Dec 202231 Dec 2023: revenue 3.70B; earnings 0.60B; profit margin 16.17%31 Dec 202331 Dec 2024: revenue 4.24B; earnings 0.03B; profit margin 0.77%31 Dec 202431 Dec 2025: revenue 5.14B; earnings 1.29B; profit margin 25.03%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$119.69(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$119.69High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning INCY

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 31 Mar 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$1.43B
Profit margin
26.71%
Return on assets · 12 month
21.88%
Index membership
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.53M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-2.93%*
Total return · month
-0.97%*
Total return · quarter
7.44%*
Total return · half year
36.42%*
Total return · year to date
24.72%*
Total return · 1 year
46.85%*
Total return · 3 years
113.24%*
Total return · 5 years
79.39%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$5.36B
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

INCYTE CORPORATION Overview

View more →

(m)

(m)

SEC CIK
879169
Industry (SIC)
8731 Services-Commercial Physical & Biological Research
Country of operation
United States
Business address
1801 AUGUSTINE CUT-OFF, WILMINGTON, Delaware, 19803, United States
Fiscal year end
1231
Phone
3024986700

Similar stocks

Stock NameCountryMarket CapPE Ratio
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
IQVIA HOLDINGS INC. (IQV)United States$45.926B20.54
Absci Corp (ABSI)United States$1.775B-14.92
OmniAb, Inc. (OABI)United States$0.698B-8.05
NRC HEALTH (NRC)United States$0.450B42.50
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B